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The purpore of this study was to evaluate the influence of some 
clinical prognostic factors, including the effect of chemohor-
monotherapy, on the survival of patients with metastatic breast 
cancer. Between November 1987 and February 1990 128 women with 
chemohormonotherapy at the Division of Cancer Chemotherapy, De­
partment of Propaedeutics of Internal Medicine were followed up by 
the Oncological Dispensary-Varna. 
Table 1. Patients' characteristics and results of univariate sur­
vival analysis 
Factor Pati- Uncen- Survival (months) 
ents sored 
median mean 
Age < 45 years 35 24 14 16.1 ± 2 , 2 
> 45,5 years 93 46 21 23.8 ± 4 . 1 * 
Menopausal status 
- premenopause 46 22 14 17,3 ± 2.2 
- postmenopause 82 48 20 26,7 ± 3,6 
Histology - inf. ductal 64 31 15 15,8 ± 1,2 
- non-differentiated 22 14 23 32,8 ± 5 . 2 
- others 16 
- no histology 26 
Free period - 0-24 months 80 46 16 16,9 ± 1 , 1 
> 24 months 48 24 23 30.2 ± 4,4 
Dominant site of metastases 
- soft tissues 35 7 > 60 24.2 ± 2,5 
-bones 30 11 27 44,2 ± 5 , 5 * * 
-v iscera l 63 52 10 11,6 ± 0 , 9 * * 
Tumour burden 
- metastases in one site 68 20 29 34,6 ± 5,9 
- metastases in two sites 37 30 14 13.2 ± 1 , 2 * * 
- metastases in > 3 sites 23 20 10 10,5 ± 0 , 9 * * 
Effect of treatment 
-remission 42 9 >60 41,1 ± 6 , 2 
- n o change 40 16 29 22,9 ± 2 , 3 * * 
- progression 46 45 8 8,5 ± 0,8** 
* - p < 0,05; * * - p < 0,001 
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Patient characteristics are shown on table 1. There are 85 pa­
tients treated with CMF (Cyclophosphamid, Methotrexat, 5 - Fluor-
ouracil), 41 ones - with FEC (5 - Fluorouracil, Epirubicin, Cyclo­
phosphamide 82 ones - with antiestrogens, and 46 ones - with ovar­
iectomy and Testosteron.The response to treatment was determined 
after the third chemotherapy course according to the criteria recom­
mended by the WHO (6). The survival was calculated from the start 
of systemic therapy for metastatic disease. The prognostic factors 
were assessed by univariate analysis (Kaplan-Meier product limit es­
timation and Cox-Mantel test) and multivariate analysis (Cox's pro­
portional hazard regression model) (2,3). Factors, significantly 
associated with poor survival in the univariate analysis were: age 
under 45 years, 2 and more sites of metastases, visceral metastases 
and resistance to chemohormonotherapy. We then studied these fac­
tors in aggregate using the Cox proportional hazard model. Disease-
progression after chemohormonotherapy and visceral sites of 
metastases each had a significantly negative effect on survival; stab­
le disease had a marginaly negative effect as presented in table 2. 
Table 2. Proportional hazard regression model 
Factor Regression Standard p Relative 95% significance 
coefficient deviation risk limits 
progression 2.39 0.31 0.0001 10.9 5.06 - 23.39 
visceral 
metastases 1.13 0.43 0.0076 3.1 1.35- 7.09 
no change 0.72 0.43 0.0946 2.1 0.88- 4.74 
bone 
metastases 0.20 0.49 0.6913 1.2 0.45- 3.24 
The independent prognostic significance of the localization of 
metastases is shown by many authors usually in combination with 
short free period, negative hormone receptors, poor histologic 
grade, but most of them do not assess the predictive role of the ef­
fectiveness of systemic therapy (1,4,5,7). Our results confirm the 
prognostic significance of the systemic therapy for metastatic breast 
cancer and in such way justify the search for new more aggressive 
and effective therapeutic regimens. 
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